Why has Blueprint’s stock been sinking? Well, one analysis says the company’s results weren’t so impressive after all.
"This is fantastic for a phase I study," says Vivek Subbiah, the M.D. Anderson researcher who ran the trial with funding from BluePrint, at a press conference. "I do a lot of phase I studies."